GlassScriptPhysician profile
Evelyn Lomasney
NPI 1578869624
$8,409.12
in general payments reported to CMS, 2019-2025
34 companies · $3,252 in 2025
The $3,252 reported for 2025 was more than what 82% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $234 · 2023: $1,975 · 2024: $2,948 · 2025: $3,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,994 · Consulting Fee: $108 · Education: $73.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,993.51 |
| Consulting Fee | $107.86 |
| Education | $73.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,785.21 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $1,227.04 | 2022-2025 | Dupixent |
| Genzyme Corporation | $844.75 | 2022-2025 | |
| Glaxosmithkline, LLC. | $811.87 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $713.74 | 2023-2025 | |
| Amgen INC. | $674.13 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $373.27 | 2023-2025 | Cuvitru, Takhzyro, Eohilia |
| Abbvie INC. | $360.56 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $178.01 | 2023-2025 | Orladeyo |
| Genentech USA, INC. | $151.45 | 2024-2025 | Xolair |
| Csl Behring | $125.50 | 2024-2025 | Hizentra, Haegarda |
| Pfizer INC. | $125.00 | 2024 | |
| Adma Biomanufacturing LLC | $107.86 | 2024-2025 | |
| Galderma Laboratories, L.P. | $86.96 | 2025 | Nemluvio |
| Leo Pharma INC. | $81.73 | 2022-2025 | Anzupgo, Adbry |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $76.83 | 2022-2023 | Auvi-Q |
| Regeneron Pharmaceuticals, INC. | $73.15 | 2024-2025 | Dupixent |
| Grifols USA, LLC | $70.20 | 2023-2025 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $65.05 | 2025 | Neffy |
| Philips North America LLC | $65.00 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Octapharma USA, INC. | $56.38 | 2022-2024 | Cutaquig |
| Incyte Corporation | $52.47 | 2023-2025 | Opzelura |
| Hikma Pharmaceuticals USA | $47.70 | 2022-2023 | Ryaltris |
| Ionis Pharmaceuticals, INC. | $43.59 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $33.75 | 2024-2025 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $30.71 | 2022 | |
| Horizon Therapeutics Plc | $24.11 | 2023 | Actimmune |
| Merck Sharp & Dohme LLC | $19.63 | 2023 | |
| Aimmune Therapeutics, INC. | $18.85 | 2022 | |
| Optinose US, INC. | $18.28 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.13 | 2022 | |
| Organon LLC | $17.42 | 2025 | |
| Cycle Pharmaceuticals INC | $16.84 | 2024 | Sajazir |
| Hospira, INC. | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Lomasney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.